Element Acquires JMI Laboratories

Element Materials Technology announced on Nov. 4, 2021, that it had signed an agreement to acquire JMI Laboratories, a company specializing in performing antimicrobial resistance surveillance studies.According to a company press release this move was made to strengthen Element’s North American offerings.

JMI uses their proprietary SENTRY Antimicrobial Surveillance Program to perform antimicrobial resistance monitoring studies for FDA regulatory and new drug application submissions. The company also offers microbiology and molecular testing services to assist in development and clinical trial support.

This acquisition is the latest in a series of acquisitions Element has made throughout 2021. Most recently, they purchased a pharmaceuticals contract development and manufacturing organization, Nanosyn, in October, and an extractables and leachables specialist, Impact Analytical, in September.

“JMI’s SENTRY surveillance program, with over 20 years of data from over 130 hospitals across 40 countries, is a real differentiator,” said Jo Wetz, CEO, Element, in the press release. “Resistance to antibiotics is a clear and present threat to public health on a global scale. With JMI’s team of renowned experts, Element is now positioned to play an important role in helping to address the growing risk of antimicrobial resistance.”

“After 20 years of operation and having built a strong reputation for our expertise and client relationships, we are proud to be joining the Element group,” said Andrew Fuhrmeister, CEO, JMI, in the press release.“This move will bring us wider global access through the Element network and will allow us to work within the expanded life sciences offering, building industry leadership.”

Source: Element